Omnicell (OMCL) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

$0.94

Estimate

$0.47

Surprise

+101.1%

Score at report (before → after)

5.6 → 6.1/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Omnicell (OMCL) beat the $0.47 estimate with diluted EPS of $0.94 — a large 101.1% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.6/10) to Hold at 6.1/10 after the report.

TrendMatrix currently rates OMCL Hold at 5.6/10.

3 of the last 4 quarters beat the estimate; this quarter's +101.1% surprise compares with a +47.1% four-quarter average. Next scheduled report: 2026-10-29.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$34.82

Price target

$50.34

Stop

$32.38

Upside to target

+44.6%

Reward-to-risk

6.1:1

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Health Information Services

Market cap

$1.58B

P/E (fwd)

16.7

P/E (ttm)

41.5

52-week range

$29.06–$55.00

Off 52-week high

36.7%

RSI (14)

36

Volume vs avg

1.01×

Score today

5.6/10